Stocktoria
Whitehawk Therapeutics, Inc. WHWK
Whitehawk Therapeutics, Inc. (WHWK) earns a Piotroski F-score of 2/9 (weak financial health), with an Altman Z″ in the safe zone. It pays a dividend yielding 1.97% (safety: no dividend). FY2025 revenue was $7.1M at a -288.3% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Beneish M-score: -2.16 — grey zone (between the usual thresholds). A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 2/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · safe zone
| Component | Value |
|---|---|
| Working capital / assets | 0.892 |
| Retained earnings / assets | -2.342 |
| EBIT / assets | -0.758 |
| Equity / liabilities | 9.388 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| WHWK | Whitehawk Therapeutics, Inc. | 2/9 | 2.98 | — | -72.5% |
| OVID | Ovid Therapeutics Inc. | 1/9 | 0.8 | — | -96.8% |
| IMNM | Immunome Inc. | 3/9 | 13.87 | — | — |
| XENE | Xenon Pharmaceuticals Inc. | 2/9 | 6.89 | — | — |
| ADAG | Adagene Inc. | 4/9 | -9.75 | — | — |
| CRNX | Crinetics Pharmaceuticals, Inc. | 2/9 | 6.19 | — | — |
| ACRS | Aclaris Therapeutics, Inc. | 2/9 | -18.21 | — | -58.2% |
About Whitehawk Therapeutics, Inc.
Whitehawk Therapeutics, Inc., a clinical-stage oncology therapeutics company that develops technologies to establish tumor biology for cancer treatments. It provides three next generation antibody drug conjugates (ADC) portfolio to treat cancer. The company was formerly known as Aadi Bioscience, Inc. and changed its name to Whitehawk Therapeutics, Inc. in August 2021. Whitehawk Therapeutics, Inc. was incorporated in 2007 and is headquartered in Morristown, New Jersey.
FAQ
Is WHWK financially healthy?
Whitehawk Therapeutics, Inc.'s Piotroski F-score is 2/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the safe zone.
Does WHWK pay a dividend, and is it safe?
Yes. Whitehawk Therapeutics, Inc. pays a dividend yielding about 1.97% with a None payout ratio, rated “no dividend” for safety.
How profitable is WHWK?
In FY2025, Whitehawk Therapeutics, Inc. had a net margin of -288.3% and a return on equity of -15.1%.
What is the analyst price target for WHWK?
The average Wall-Street price target for Whitehawk Therapeutics, Inc. is $7.20, about 52.9% above the recent price, from 5 analysts (consensus: buy).
Is WHWK a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Whitehawk Therapeutics, Inc.: a Piotroski F-score of 2/9, an Altman Z″ in the safe zone, a dividend yield of 1.97%. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.